Shire PLC (NASDAQ:SHPG) saw an uptick in trading volume on Tuesday . 2,575,870 shares traded hands during mid-day trading, an increase of 8% from the previous session’s volume of 2,376,483 shares.The stock last traded at $194.18 and had previously closed at $186.31.

Several brokerages have commented on SHPG. BTIG Research reiterated a “positive” rating on shares of Shire PLC in a research note on Tuesday. Shore Capital reiterated a “buy” rating on shares of Shire PLC in a research note on Thursday, July 7th. Zacks Investment Research upgraded shares of Shire PLC from a “hold” rating to a “buy” rating and set a $208.00 price target on the stock in a research note on Tuesday, July 5th. Jefferies Group reiterated a “buy” rating on shares of Shire PLC in a research note on Friday, July 1st. Finally, Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Shire PLC in a research note on Tuesday, June 28th. Two research analysts have rated the stock with a hold rating and twenty-four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $236.13.

The company has a market capitalization of $38.52 billion and a PE ratio of 29.35. The company has a 50 day moving average price of $182.23 and a 200-day moving average price of $175.87.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Friday, April 29th. The biopharmaceutical company reported $3.19 EPS for the quarter, topping the Zacks’ consensus estimate of $3.05 by $0.14. During the same quarter in the previous year, the company earned $2.08 earnings per share. The company had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.71 billion. Shire PLC’s quarterly revenue was up 14.9% compared to the same quarter last year. On average, equities analysts expect that Shire PLC will post $4.19 earnings per share for the current year.

A number of hedge funds and institutional investors recently modified their holdings of SHPG. Johnston Asset Management Corp increased its position in shares of Shire PLC by 0.3% in the fourth quarter. Johnston Asset Management Corp now owns 122,920 shares of the biopharmaceutical company’s stock worth $25,199,000 after buying an additional 330 shares during the last quarter. ProShare Advisors LLC increased its position in shares of Shire PLC by 0.9% in the fourth quarter. ProShare Advisors LLC now owns 37,741 shares of the biopharmaceutical company’s stock worth $7,737,000 after buying an additional 340 shares during the last quarter. Comerica Bank increased its position in shares of Shire PLC by 3.5% in the fourth quarter. Comerica Bank now owns 12,532 shares of the biopharmaceutical company’s stock worth $2,331,000 after buying an additional 427 shares during the last quarter. Advisors Asset Management Inc. increased its position in shares of Shire PLC by 14.1% in the fourth quarter. Advisors Asset Management Inc. now owns 6,521 shares of the biopharmaceutical company’s stock worth $1,337,000 after buying an additional 805 shares during the last quarter. Finally, Seizert Capital Partners LLC increased its position in shares of Shire PLC by 22.2% in the fourth quarter. Seizert Capital Partners LLC now owns 5,345 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 970 shares during the last quarter.

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.